Stevens Capital Management LP acquired a new stake in shares of NuVasive, Inc. (NASDAQ:NUVA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 18,571 shares of the medical device company’s stock, valued at approximately $1,428,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Miles Capital Inc. increased its position in NuVasive by 0.3% during the first quarter. Miles Capital Inc. now owns 3,118 shares of the medical device company’s stock valued at $233,000 after acquiring an additional 8 shares during the last quarter. Teacher Retirement System of Texas increased its position in NuVasive by 1.0% during the second quarter. Teacher Retirement System of Texas now owns 4,040 shares of the medical device company’s stock valued at $311,000 after acquiring an additional 40 shares during the last quarter. US Bancorp DE increased its position in NuVasive by 1.7% during the first quarter. US Bancorp DE now owns 2,401 shares of the medical device company’s stock valued at $180,000 after acquiring an additional 41 shares during the last quarter. Northwestern Mutual Investment Management Company LLC increased its position in NuVasive by 0.5% during the first quarter. Northwestern Mutual Investment Management Company LLC now owns 8,720 shares of the medical device company’s stock valued at $651,000 after acquiring an additional 43 shares during the last quarter. Finally, World Asset Management Inc increased its position in NuVasive by 2.3% during the first quarter. World Asset Management Inc now owns 3,117 shares of the medical device company’s stock valued at $233,000 after acquiring an additional 69 shares during the last quarter.

In other NuVasive news, CEO Gregory T. Lucier acquired 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 29th. The shares were purchased at an average cost of $61.52 per share, for a total transaction of $123,040.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Lesley H. Howe sold 3,970 shares of the company’s stock in a transaction that occurred on Friday, August 18th. The shares were sold at an average price of $64.64, for a total value of $256,620.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have bought 14,850 shares of company stock worth $955,598. Insiders own 1.20% of the company’s stock.

NuVasive, Inc. (NASDAQ:NUVA) opened at 54.25 on Friday. The company has a market cap of $2.76 billion, a price-to-earnings ratio of 85.43 and a beta of 1.08. NuVasive, Inc. has a 1-year low of $52.85 and a 1-year high of $81.68. The stock has a 50 day moving average price of $62.55 and a 200-day moving average price of $71.98.

NuVasive (NASDAQ:NUVA) last posted its quarterly earnings data on Thursday, July 27th. The medical device company reported $0.46 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.02. NuVasive had a return on equity of 13.04% and a net margin of 3.50%. The company had revenue of $260.60 million during the quarter, compared to analyst estimates of $261.95 million. During the same period in the previous year, the business earned $0.40 EPS. NuVasive’s quarterly revenue was up 10.3% on a year-over-year basis. On average, equities research analysts forecast that NuVasive, Inc. will post $2.00 EPS for the current year.

A number of analysts recently commented on NUVA shares. Needham & Company LLC cut NuVasive from a “hold” rating to an “underperform” rating in a research report on Monday, August 28th. BTIG Research started coverage on NuVasive in a research report on Thursday, September 7th. They issued a “buy” rating and a $82.00 price target for the company. BidaskClub upgraded NuVasive from a “hold” rating to a “buy” rating in a research report on Wednesday, July 19th. Zacks Investment Research cut NuVasive from a “hold” rating to a “sell” rating in a research report on Tuesday, June 27th. Finally, Royal Bank Of Canada upped their price target on NuVasive from $76.00 to $85.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 6th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have given a buy rating to the stock. NuVasive presently has a consensus rating of “Buy” and a consensus price target of $79.92.

WARNING: “Stevens Capital Management LP Acquires New Stake in NuVasive, Inc. (NUVA)” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/09/23/stevens-capital-management-lp-acquires-new-stake-in-nuvasive-inc-nuva.html.

NuVasive Profile

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Institutional Ownership by Quarter for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.